Answers are grounded in this paper and cite their sources.
Suvorexant is a dual orexin antagonist currently in Phase III clinical trials for the modulation of sleep and is being developed by Merck. Recent Phase III results showed that patients taking the drug fell asleep faster and slept longer than those on placebo.
No takes yet. Share an insight, caveat, or question.
Corey R. Hopkins (2012) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: